- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2026
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/34377
| Title: | IMMUNOLOGICAL BIOMARKERS IN ANTIPHOSPHOLIPID SYNDROME: PERSPECTIVES OFFERED BY OMICS TECHNOLOGIES FOR DIAGNOSIS AND RISK STRATIFICATION |
| Authors: | Paduraru, Marius |
| Keywords: | APS;antiphospholipid syndrome;immunological biomarkers;omics technologies;risk stratification |
| Issue Date: | 2026 |
| Publisher: | Centrul Editorial-Poligrafic Medicina |
| Citation: | Paduraru, Marius. IMMUNOLOGICAL BIOMARKERS IN ANTIPHOSPHOLIPID SYNDROME: PERSPECTIVES OFFERED BY OMICS TECHNOLOGIES FOR DIAGNOSIS AND RISK STRATIFICATION. In: MedEspera 2026, p. 562. ISBN 978-9975-82-486-6. |
| Abstract: | Introduction. Antiphospholipid syndrome (APS) is a systemic autoimmune disease in the presence of persistent antiphospholipid antibodies that leads to arterial or venous thrombosis and obstetric complications. Various clinical manifestations denote the complex pathogenetic mechanisms involved in antiphospholipid syndrome. The laboratory markers currently used help us to establish the diagnosis, but do not provide sufficient information about clinical variability or the occurrence of complications. In recent years, there is growing interest in biomarkers identified through omics technologies as they provide new insights into the molecular mechanisms involved in APS. Aim of study. The purpose of the paper was to analyze the data on immunological biomarkers identified by omics technologies and to evaluate their usefulness in the diagnosis, risk and individualized management of patients with APS. Methods and materials. The scientific literature was reviewed using the databases PubMed, Scopus and Web of Science, The Scientific Library of the Nicolae Testemitanu State University of Medicine and pharmacy. Included are studies published in the period 2015-2026, selected on the basis of relevance, methodological quality and clinical applicability. In total, 29 studies were analyzed. Results. The studies analyzed show that biomarkers identified by omics technologies can help us better differentiate the clinical subgroups of APS. A genomic study of 5,485 individuals showed associations in the HLA-DRA and STAT1-STAT4 regions, as well as 34 additional loci involved in susceptibility to the disease. Transcriptomic analysis in 112 patients identified three Type I interferon activation profiles that show an important role of interferon-mediated immune response in APS. Also, 39 Altered circulating microRNAs were found in patients with APS. A group of ten reports of microRNAs was associated with thrombosis, obstetric complications and inflammatory activity. The Proteomic profile identified up to 6,398 proteins and revealed patterns of complement activation, thromboinflammation and endothelial lesions, more characteristic in severe clinical forms of the disease. Conclusions. Immunological biomarkers identified by omics technologies provide new insights for determining the biological heterogeneity of APS. The introduction of these data helps us in clinical research, diagnostic improvement and more accurate risk assessment and, in the future, the development of personalized management strategies for patients with APS disease. |
| metadata.dc.relation.ispartof: | MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026 |
| URI: | https://medespera.md/documents/abstract-book-4.pdf https://repository.usmf.md/handle/20.500.12710/34377 |
| ISBN: | 978-9975-82-486-6 |
| Appears in Collections: | MedEspera 2026
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|